Common stock, $0.001 par value
- Symbol
- CTXR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Citius Pharmaceuticals, Inc.
CTXRNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On October 26, 2026, our wholly-owned subsidiary, Citius Oncology, Inc., issued a press release announcing preliminary, unaudited LYMPHIR® (denileukin diftitox-cxdl) unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026.…
Company context
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I - III CTCL after at least one prior systemic therapy. Management estimates the initial CTCL market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets, and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning. For more information, please visit www.citiusonc.com.
Current securities
Historical securities (1)
Recent company filings
- Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingAug 21, 2026
- 10-Q filingAug 14, 2026
- Results of Operations and Financial ConditionAug 14, 2026
- SCHEDULE 13G/A - filed by CVI Investments, Inc. regarding Citius Pharmaceuticals, Inc.Aug 14, 2026
- Other EventsAug 5, 2026
Registered securities in this filing
Citius Pharmaceuticals, Inc. · 8-K · Filed 2026-10-26
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations
and Financial Condition.
On October 26, 2026, our wholly-owned
subsidiary, Citius Oncology, Inc., issued a press release announcing preliminary, unaudited LYMPHIR® (denileukin diftitox-cxdl)
unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026. A copy of the press
release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item
2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934
(the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Filed exhibits (1)
Exhibit 99.1 Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 CRANFORD, N.J., October 26, 2026 - Citius Oncology, Inc. (“Citius Oncology” or the “Company”) (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today announced preliminary, unaudited LYMPHIR® (denileukin diftitox-cxdl) unit sales to U.S. wholesalers and institutional vial orders for the fiscal fourth quarter ended September 30, 2026. “The fiscal fourth quarter showed continued institutional demand for LYMPHIR. Unit sales to wholesalers more than doubled as our expanded commercial team reached nationwide coverage in August,” said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology. “We are now more than halfway to our goal of having LYMPHIR on formulary at 100 priority institutions by calendar year-end. As we enter fiscal 2027, we expect the momentum we built in the fourth quarter to carry forward, with growing institutional demand, deeper penetration into academic and community tre…
Open exhibit ↗